Naftidrofuryl

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Naftidrofuryl
Naftidrofuryl.svg
Systematic (IUPAC) name
(RS)-2-(diethylamino)ethyl 3-(1-naphthyl)-2-(tetrahydrofuran-2-ylmethyl)propanoate
Clinical data
Trade names Praxilene
AHFS/Drugs.com International Drug Names
Legal status
Routes of
administration
Oral
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 1 - 3.5 hours
Identifiers
CAS Registry Number 31329-57-4 YesY
ATC code C04AX21
PubChem CID: 4417
ChemSpider 4264 YesY
UNII 42H8PQ0NMJ YesY
ChEMBL CHEMBL1620794
Chemical data
Formula C24H33NO3
Molecular mass 383.524 g/mol
 YesY (what is this?)  (verify)

Naftidrofuryl (INN, also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator. It is also claimed to enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.[1] It is also licenced for the treatment of intermittent claudication due to peripheral arterial disease.

Naftidrofuryl is marketed under the trade names Artocoron; Azunaftil; Di-Actane; Dusodril; Enelbin; Frilix; Gevatran; Iridus; Iridux; Luctor; Nafti; Naftoling; Naftodril; Nafoxal; Praxilene; Sodipryl retard; Vascuprax.

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[2]

Naftidrofuryl may be effective for relieving the pain of muscle cramps.[3]

Synthesis[edit]

Prepn: Szarvasi, Bayssat, FR 1363948  corresp to U.S. Patent 3,334,096 (1964, 1967 both to LIPHA);[4] eidem[5]

Adverse Effects[edit]

Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[1]

References[edit]

  1. ^ a b Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014. 
  2. ^ http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
  3. ^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124. 
  4. ^ Szarvasi et al., Compt. Rend. 260, 3095 (1965).
  5. ^ Bull. Soc. Chim. Fr. 1966, 1838.